
ENDRA Life Sciences Long-Term Debt | NDRA
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt ENDRA Life Sciences
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 291 K | 363 K | 487 K | - | 366 K | 547 K | 272 K | 343 K | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 547 K | 272 K | 381 K |
Quarterly Long-Term Debt ENDRA Life Sciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 253 K | 291 K | 327 K | 363 K | 397 K | 429 K | 461 K | 487 K | 49.8 K | 98.4 K | - | 192 K | 237 K | 281 K | 324 K | 366 K | 406 K | 444 K | 482 K | 518 K | 553 K | 586 K | 252 K | 272 K | 290 K | 272 K | 272 K | 343 K | 359 K | 343 K | 343 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 586 K | 49.8 K | 343 K |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | ||
|
Renalytix AI plc
RNLX
|
41 K | - | 5.66 % | $ 22.7 M | ||
|
Meridian Bioscience
VIVO
|
25 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
30 K | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
6.6 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
2.61 B | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
233 M | - | -11.32 % | $ 1.1 M | ||
|
Brainsway Ltd.
BWAY
|
4.8 M | $ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.7 M | $ 13.46 | 1.05 % | $ 142 M | ||
|
Medpace Holdings
MEDP
|
114 M | $ 609.81 | -3.81 % | $ 17.6 B | ||
|
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
29.6 M | - | - | $ 608 M | ||
|
RadNet
RDNT
|
1.06 B | $ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
53 K | - | -1.84 % | $ 15.3 M | ||
|
IDEXX Laboratories
IDXX
|
375 M | $ 675.24 | -2.09 % | $ 54.3 B | ||
|
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
50 M | $ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
3.05 B | $ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
2.14 B | $ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
18.4 B | $ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
53.8 M | $ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
163 K | $ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
138 M | $ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
1.5 B | $ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
3.48 M | $ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
279 M | $ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
13.9 B | $ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
9.64 M | $ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
2.09 B | $ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
486 M | $ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
118 M | $ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
360 K | $ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
19.7 M | $ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
1.65 M | $ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
752 K | $ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
569 M | $ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
35.6 M | $ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
2.13 B | $ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
2.87 B | $ 186.79 | -1.88 % | $ 14.6 B |